Adana Research and Training Center, Department of Ophthalmology, Faculty of Medicine, Baskent University, Adana, Turkey.
Department of Ophthalmology, Faculty of Medicine, Baskent University, Ankara, Turkey.
Eur J Ophthalmol. 2021 Jan;31(1):179-183. doi: 10.1177/1120672119886989. Epub 2019 Nov 13.
To report the results of intravitreal ranibizumab injection as primary therapy in aggressive posterior retinopathy of prematurity, the process of the disease, and the additive treatments performed.
This retrospective case review included 15 eyes of 8 premature babies with aggressive posterior retinopathy of prematurity who were initially treated with intravitreal ranibizumab injection. The documented data were gestational age, birth weight, gender, postmenstrual age at intravitreal ranibizumab injection, zone of retinopathy of prematurity, reactivation time of disease, iris neovascularization, retinal hemorrhage, anatomical outcome, and additional treatment.
Median gestational age at birth was 26 (range, 23-27) weeks, birth weight was 730 (range, 550-970) g, and postconceptional age at aggressive posterior retinopathy of prematurity diagnosis and intravitreal ranibizumab injection was 35 (range, 33-35) weeks. Intravitreal ranibizumab injection was performed as primary treatment. Two eyes necessitated a second intravitreal ranibizumab injection. The reactivation of retinopathy of prematurity was 5 (range, 3-7) weeks after intravitreal ranibizumab injection. Recurrence of the disease in Zone II was treated with laser photocoagulation. A favorable outcome was obtained in all eyes (100%).
Aggressive posterior retinopathy of prematurity is a serious, rapidly progressing form of retinopathy of prematurity that requires quick and proper management. This study indicates that primary treatment with ranibizumab and laser photocoagulation on recurrence provide favorable anatomical outcomes.
报告玻璃体内雷珠单抗注射作为早产儿后部进展性视网膜病变的主要治疗方法的结果，包括疾病的发展过程和进行的附加治疗。
本回顾性病例研究纳入了 8 名患有后部进展性早产儿视网膜病变的早产儿的 15 只眼，这些早产儿最初接受了玻璃体内雷珠单抗注射治疗。记录的数据包括胎龄、出生体重、性别、玻璃体内雷珠单抗注射时的矫正胎龄、早产儿视网膜病变区、疾病复发时间、虹膜新生血管、视网膜出血、解剖学结果和附加治疗。
中位出生胎龄为 26 周（范围 23-27 周），出生体重为 730 克（范围 550-970 克），诊断为后部进展性早产儿视网膜病变和玻璃体内雷珠单抗注射时的矫正胎龄为 35 周（范围 33-35 周）。玻璃体内雷珠单抗注射作为主要治疗方法。有 2 只眼需要进行第二次玻璃体内雷珠单抗注射。玻璃体内雷珠单抗注射后 5 周（范围 3-7 周）视网膜病变复发。区 2 的疾病复发采用激光光凝治疗。所有眼（100%）均获得良好的解剖学结果。
后部进展性早产儿视网膜病变是一种严重且快速进展的早产儿视网膜病变，需要及时和恰当的管理。本研究表明，雷珠单抗作为主要治疗方法，在疾病复发时采用激光光凝治疗，可获得良好的解剖学结果。
